NDC Changes for Herceptin and Lucentis Drug Notice

Information posted August 4, 2017

Genentech has notified the Vendor Drug Program (VDP) of National Drug Code (NDC) changes for the drugs Herceptin and Lucentis.

The older NDCs are currently present on the July version of the NDC-to-HCPCS crosswalk. The new NDCs will be added to the crosswalk once the VDP receives the quarterly rebate file from CMS.

This will be done no later than September of 2017, with a retroactive relationship start date dated back to the package introduction dates and with an open-ended end date, as indicated in the following table:

Old NDC	New NDC	HCPCS	New Begin Date	HCPCS Description	NDC Description
50242-0080-01	50242-0080-02	J2778	5/15/2017	Injection, ranibizumab, 0.1 mg	LUCENTIS 0.5 MG VIAL
50242-0082-01	50242-0082-02	J2778	5/15/2017	Injection, ranibizumab, 0.1 mg	LUCENTIS 0.3 MG VIAL
50242-0134-68	50242-0132-01	J9355	5/30/2017	Injection, trastuzumab, 10 mg	HERCEPTIN 150 MG VIAL (vial changed from 440mg to 150mg)

Genentech also introduced a Lucentis pre-filled syringe in January, which will be added to the crosswalk at the same time. See the following table:

New NDC	HCPCS	New Begin Date	HCPCS Description	NDC Description
50242-0080-03	J2778	1/30/2017	Injection, ranibizumab, 0.1 mg	Lucentis 0.5 mg Prefilled Syringe

Affected claims submitted before the filing deadlines will be reprocessed for these products after the NDCs are added to the crosswalk. Providers may receive reimbursement, which will be reflected on future Remittance and Status (R&S) Reports.

More information about the NDC-to-HCPCS crosswalk is available at the Vendor Drug Program website.